Physician profile
John J Park
NPI 1205862075
$1,312.09
in general payments reported to CMS, 2019-2025
20 companies · $182 in 2025
The $182 reported for 2025 was more than what 79% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2021: $28.57 · 2023: $64.93 · 2024: $475 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433 · Travel and Lodging: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.74 |
| Travel and Lodging | $289.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $304.58 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Sun Pharmaceutical Industries INC. | $273.89 | 2023-2025 | Cequa |
| Nevro Corp. | $217.72 | 2019 | |
| Allergan, INC. | $176.92 | 2019 | |
| Collegium Pharmaceutical, INC. | $39.97 | 2019 | |
| Daiichi Sankyo INC. | $37.14 | 2019 | |
| Harrow Eye, LLC | $33.64 | 2025 | Vevye |
| Takeda Pharmaceuticals U.S.A., INC. | $31.57 | 2024-2025 | Gattex |
| Boston Scientific Corporation | $28.57 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $25.45 | 2024 | Exparel |
| Sight Sciences, INC. | $21.54 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $17.27 | 2025 | Syfovre |
| Arbor Pharmaceuticals, INC. | $14.39 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.34 | 2019 | |
| Bausch & Lomb Americas INC. | $14.08 | 2024 | Miebo, Xiidra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12.86 | 2019 | |
| Kaleo, INC. | $12.45 | 2019 | |
| Biodelivery Sciences International, INC. | $12.34 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $12.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.